Research in North Carolina - Piedmont Triad Region

Increased Access for Better Care

03.07.14 | By

Each patient is unique, which means that medicines and therapies often need to be tailored to fit individual needs to ensure the best possible care. While the research and development (R&D) pipeline holds the promise of new, innovative treatments for those suffering from a variety of diseases, it is important to explore all options to improve patient health.

The Pathway to Progress

03.06.14 | By

This post originally appeared on the Age of Personalized Medicine.

Participation in Clinical Trials Critical to Development of New Medicines for Patients

02.26.14 | By

Developing new medicines is a lengthy and complex process, relying heavily on volunteer participation to evaluate potential therapies for safety and effectiveness in clinical trials. Without the patients who volunteer to participate in clinical research, the development of new treatments would not be possible.

Challenges in Patient Recruitment

#RarePOV Conversation Generates Strong Enthusiasm for Rare Disease Day on February 28th

02.12.14 | By

In last week’s #RarePOV tweetchat, leading rare disease advocacy organizations and individual patient advocates came together to share resources and plans for the upcoming international Rare Disease Day.

Special 301 Submission

Sickle Cell Community Encouraged to Share Perspective with FDA

02.07.14 | By

As highlighted in an earlier Catalyst post, PhRMA is partnering with Genetic Alliance on an exciting project to enhance patient engagement in the Food and Drug Administration’s (FDA) Patient-Focused Drug Development initiative. Genetic Alliance recently launched the first pilot program, partnering with four trusted organizations serving the sickle cell community.

Pilot Programs to Focus on Alzheimer’s Disease, Autoimmune Disorders and Type 2 Diabetes

Washington, D.C. (February 4, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) has joined the National Institutes of Health (NIH),  10 biopharmaceutical companies and several non-profit disease foundations in a partnership to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease.

Public-Private Partnerships Key to Addressing Public Health Challenges

02.04.14 | By

NIH LogoA groundbreaking new partnership was announced earlier today by the National Institutes of Health (NIH).

Soaring to New Heights

01.31.14 | By

What does working in a lab have in common with flying an airplane? A great deal according to the next researcher highlighted in our “I am Research, Progress, Hope” series, Dowdy Jackson, head of the Antibody Drug Conjugate (ADC) Biology group at Agensys, an affiliate of Astellas.


Subscribe to RSS - Innovation